Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502
Authors:
- Eyal C. AttarEAEyal C. Attar
- Jeffrey L. JohnsonJJJeffrey L. Johnson
- Philip C. AmreinPAPhilip C. Amrein
- Gerard LozanskiGLGerard Lozanski
- Martha WadleighMWMartha Wadleigh
- Daniel J. DeAngeloDDDaniel J. DeAngelo
- Jonathan E. KolitzJKJonathan E. Kolitz
- Bayard L. PowellBPBayard L. Powell
- Peter VoorheesPVPeter Voorhees
- Eunice S. WangEWEunice S. Wang
- William BlumWBWilliam Blum
- Richard M. StoneRSRichard M. Stone
- 1 March 2013
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (7) , 923-929
Abstract
Purpose: The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combination with consolidation chemotherapy consisting of intermediate-dose cytarabine (Int-DAC).Patients and Methods: Ninety-five adults (age 60 to 75 years; median, 67 years) with previously untreated AML (including therapy-related and previous myelodysplastic syndrome) received bortezomib 1.3 mg/m2intravenously (IV) on days 1, 4, 8, and 11 with daunorubicin 60 mg/m2on days 1 through 3 and cytarabine 100 mg/m2by continuous IV infusion on days 1 through 7. Patients who achieved complete remission (CR) received up to two courses of consolidation chemotherapy with cytarabine 2 gm/m2on days 1 through 5 with bortezomib. Three cohorts with escalating dose levels of bortezomib were tested (0.7, 1.0, and 1.3 mg/m2). Dose-limiting toxicities were assessed during the first cycle of consolidation. The relationship between cell surface expression of CD74 and clinical outcome was assessed.Results: Frequency of CR was 65% (62 of 95), and 4% of patients (four of 95) achieved CR with incomplete platelet recovery (CRp). Eleven patients developed grade 3 sensory neuropathy. Bortezomib plus Int-DAC proved tolerable at the highest dose tested. Lower CD74 expression was associated with CR/CRp (P = .04) but not with disease-free or overall survival.Conclusion: The addition of bortezomib to standard 3 + 7 daunorubicin and cytarabine induction chemotherapy for AML resulted in an encouraging remission rate. The maximum tested dose of bortezomib administered in combination with Int-DAC for remission consolidation was 1.3 mg/m2and proved tolerable. Further testing of this regimen is planned.Keywords
This publication has 19 references indexed in Scilit:
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaBlood, 2012
- The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trialBritish Journal of Haematology, 2009
- Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous LeukemiaClinical Cancer Research, 2008
- Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 statusCancer Chemotherapy and Pharmacology, 2006
- Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survivalBlood, 2006
- Class II-Associated Invariant Chain Peptide Expression on Myeloid Leukemic Blasts Predicts Poor Clinical OutcomeCancer Research, 2004
- Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 studyBlood, 2004
- Preferential induction of apoptosis for primary human leukemic stem cellsProceedings of the National Academy of Sciences, 2002
- Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatmentBlood, 2001
- Proteasome inhibitors: a novel class of potent and effective antitumor agents.1999